Urol. praxi, 2011; 12(3): 158-163

Bone metastasis in prostate cancer and other urological malignancies - 1st part

MUDr.Otakar Čapoun
Urologická klinika VFN a 1. LF UK v Praze

Metastatic prostate cancer is a serious disease with the only palliative therapy possible. In almost all cases castration-resistant prostate

cancer patients will die with bone metastasis. Skeletal lesions are associated with greater morbidity and pain, that result in the patients’

lower quality of life. Novel therapeutic methods utilize results of the research of metastatic process pathofysiology, especially of factors

affecting formation and progression of bone lesion. Laboratory markers together with imaging methods contribute to the clinical staging

and treatment response assessment, and are used in mathematical models for the evaluation of prognosis. Skeletal complications

represent a great risk of health condition and self-sufficiency worsening as well as shortening of overall survival.

Keywords: prostate cancer, bone metastasis, diagnostic methods

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čapoun O. Bone metastasis in prostate cancer and other urological malignancies - 1st part. Urol. praxi. 2011;12(3):158-163.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005; 96(7): 985-989. Go to original source... Go to PubMed...
    2. Babjuk M, Matoušková M, Fínek J, et al. Konsensuální doporučené postupy v uroonkologii. Praha: Galén, 2009: 1-126.
    3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2): 6243-6249. Go to original source... Go to PubMed...
    4. Lipton A, Colombo-Berra A, Bukowski RM, et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004; 10(18 Pt 2): 6397-6403. Go to original source... Go to PubMed...
    5. Taher AN, Kotb MH. Bone metastases in muscle-invasive bladder cancer. J Egypt Natl Canc Inst. 2006; 18(3): 203-208. Go to PubMed...
    6. Kalaitzis C, Bantis A, Tsakaldimis G, et al. Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report. J Med Case Reports. 2009; 31(3): 8702. Go to original source... Go to PubMed...
    7. SVOD (System for Visualization of Oncological Dates version 6); http://www.svod.cz.
    8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573. Go to original source...
    9. Fuchs E. Das Sarkom des Uvealtractus. Wien, 1882. Graefe's Archiv für Ophthalmologie, XII, 2, p. 233.
    10. Makino S. The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum 1959; 15(Suppl 1): 196-198.
    11. Lin EH, Jiang Y, Deng Y, et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells:, ,seed and soil" theory revisited. Gastrointest Cancer Res. 2008; 2(4): 169-174.
    12. Regenbrecht CR, Lehrach H, Adjaye J. Stemming Cancer: Functional Genomics of Cancer Stem Cells in Solid Tumors. Stem Cell Rev 2008; 4(4): 319-328. Go to original source... Go to PubMed...
    13. Harless WW. Cancer treatments transform cancer cell phenotype. Cancer Cell Int. 2011; 11(1): 1. Go to original source... Go to PubMed...
    14. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 2010; 5(8): e12445. Go to original source... Go to PubMed...
    15. Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res 2008; 10(Suppl 1): S2. Go to original source... Go to PubMed...
    16. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006; 12(20 Pt 2): 6213-6216. Go to original source... Go to PubMed...
    17. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 1489-1494. Go to original source...
    18. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. JClin Oncol 2005; 23: 7897-7903. Go to original source... Go to PubMed...
    19. Pacík D. Význam inhibice RANK ligandu v léčbě kostních komplikací u pacientů s metastazujícím karcinomem prostaty. Urol List 2010; 8(4): 58-61.
    20. Brown JE, Sim S. Evolving role of bone biomarkers in castration-resistant prostate cancer. Neoplasia. 2010; 12(9): 685-696. Go to original source... Go to PubMed...
    21. Kamiya N, Suzuki H, Yano M, et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology. 2010; 75(6): 1446-1451. Go to original source... Go to PubMed...
    22. Koopmans N, de Jong IJ, Breeuwsma AJ, et al. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol. 2007; 178(3 Pt 1): 849-853. Go to original source... Go to PubMed...
    23. Rana A, Karamanis K, Lucas MG, et al. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol. 1992; 69(3): 277-281. Go to original source... Go to PubMed...
    24. Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010; 58(1): 1-7. Go to original source... Go to PubMed...
    25. Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001; 88(3): 226-230. Go to original source... Go to PubMed...
    26. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol. 2010 Oct 28. Go to original source... Go to PubMed...
    27. Dotan ZA. Bone imaging in prostate cancer. Nat Clin Pract Urol. 2008; 5(8): 434-444. Go to original source... Go to PubMed...
    28. Van der Wall H. The evaluation of malignancy: metastatic bone disease. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. Vol 2. 2nd ed. New York, NY: Churchill Livingstone, 1998: 1169.
    29. Brown ML. Bone scintigraphy in benign and malignant tumors. Radiol Clin North Am. 1993; 31(4): 731-738. Go to original source... Go to PubMed...
    30. Lin K, Szabo Z, Chin BB, et al. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999; 24: 579-582. Go to original source... Go to PubMed...
    31. Thomson V, Pialat J-B, Gay F, et al. Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am J Clin Oncol. 2008; 31: 285-292. Go to original source... Go to PubMed...
    32. Heidenreich A, Albers P, Classen J, et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int. 2010; 85(1): 1-10. Go to original source... Go to PubMed...
    33. Lecouvet FE, Simon M, Tombal B, et al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol. 2010; 20(12): 2973-2982. Go to original source... Go to PubMed...
    34. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007; 46(5): 161-168. Go to original source... Go to PubMed...
    35. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22: 2942-2953. Go to original source... Go to PubMed...
    36. Beheshti M, Vali R, Waldenberger P, Fitz F, et al. Detection of bone metastases in patients with prostate cancer by 18 F fluorocholine and 18 F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35(10): 1766-1774. Go to original source... Go to PubMed...
    37. Lipton A. Future treatment of bone metastases. Clin Cancer Res 2006; 12 Suppl: 6305s-6308s. Go to original source... Go to PubMed...
    38. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008; 14(5): 317-322.
    39. Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011; 48(1): 160-166. Go to original source... Go to PubMed...
    40. Murray RML, Grill V, Crinis N, et al. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostate cancer. J Clin Endocrinol Metab 2001; 86: 4133-4138. Go to original source... Go to PubMed...
    41. Berruti A, Tucci M, Mosca A, et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer. 2005; 93(6): 633-638. Go to original source... Go to PubMed...
    42. Belej K, Kaplan O. Možnosti systémové léčby karcinomu prostaty. Urolog. pro Praxi, 2009; 10(3): 168-174.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.